Document Detail


Considerations of current methods for drug selection in treating malignant ventricular arrhythmias.
MedLine Citation:
PMID:  3661427     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The current burgeoning interest in antiarrhythmic drugs derives in large measure from a growing concern with the enormous problem of sudden cardiac death. Until the latter half of the twentieth century, beyond a nodding acknowledgment of its massive prevalence, this syndrome received but scant attention from the medical profession. In the early 1960s a number of insights changed perceptions as well as practice. These related to 4 postulates: (1) sudden cardiac death, in the majority of victims, was due to ventricular tachyarrhythmias either initiated by or culminating rapidly in ventricular fibrillation; (2) the lethal arrhythmia was not the consequence of irreversible pathomorphologic impairment of the contractile apparatus, but rather the expression of an electrophysiologic derangement; (3) the triggering of ventricular fibrillation was the result of an electrical accident both reversible as well as preventable; (4) the potential victim was identifiable either by the presence of certain grades of ventricular ectopic activity or by exposure of repetitive ectopic activity or by exposure of repetitive ventricular arrhythmias by electrophysiologic techniques. The innovations that have led to these insights and their consequences have been numerous and continuous. Among these are direct current defibrillation, cardioversion, coronary care units, bystander-initiated cardiopulmonary resuscitation, ambulatory electrocardiographic monitoring and exercise stress testing for exposing ventricular arrhythmias, electrophysiologic provocative testing and mapping techniques, overdrive programmable pacemakers as well as implantable defibrillators and cardioverters, and surgical, electrical and laser techniques for ablating the nidus or interrupting the pathways of the arrhythmias.
Authors:
B Lown; P J Podrid; T B Graboys; S Lampert; C Blatt
Related Documents :
6851037 - Reduction in infarct size, arrhythmias and chest pain by early intravenous beta blockad...
9323077 - Predictors of arrhythmic death and cardiac arrest in the esvem trial. electrophysiologi...
11786157 - The valsalva maneuver in chagas disease patients without cardiopathy.
18368697 - Scn5a variants in japanese patients with left ventricular noncompaction and arrhythmia.
3346747 - Radionuclide bone imaging findings in recurrent calvarial infarction in sickle cell dis...
18378337 - Treatment of right heart thromboemboli: the need of a randomized multicentre trial.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  The American journal of cardiology     Volume:  60     ISSN:  0002-9149     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  1987 Oct 
Date Detail:
Created Date:  1987-11-19     Completed Date:  1987-11-19     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  3F-9F     Citation Subset:  AIM; IM    
Affiliation:
Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts 02115.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anti-Arrhythmia Agents / blood,  therapeutic use*
Arrhythmias, Cardiac / blood,  drug therapy*,  physiopathology
Drug Administration Schedule
Electrocardiography
Electrophysiology
Exercise Test / methods
Heart Ventricles / physiopathology
Humans
Monitoring, Physiologic
Physical Exertion / drug effects
Grant Support
ID/Acronym/Agency:
HL-07776/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Anti-Arrhythmia Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Comparison of amplitude-modulated (direct) and frequency-modulated ambulatory techniques for recordi...
Next Document:  Combined hemodynamic and scintigraphic assessment of piroximone (MDL 19,205) and comparison with dob...